<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945178</url>
  </required_header>
  <id_info>
    <org_study_id>D5090C00021</org_study_id>
    <secondary_id>EudraCT No.: 2009-012114-43</secondary_id>
    <nct_id>NCT00945178</nct_id>
  </id_info>
  <brief_title>Double-blind Placebo-controlled 2-part Study Assessing the Safety, Tolerability and PK of AZD1386 in Healthy Volunteers</brief_title>
  <official_title>A Single-centre, Randomised, Double-blind, Placebo-controlled, Two-part Study to Assess Safety, Tolerability, Pharmacokinetics of Orally Administered AZD1386</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate how a new formulation of the study drug is absorbed, metabolised
      and distributed through the body, as well as its safety and tolerability in higher doses when
      given as single and multiple doses and as a single dose in the presence and absence of
      naproxen.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated due to results in another study (NCT00878501).
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety variables (adverse events, vital signs, ECG, safety lab)</measure>
    <time_frame>Assessments performed at frequent timepoints (predose then ranging from 15 minutes to every 12 hours) on Days -1 to Day 3 (Part A: treatment period 1 and Part B) or Day-1 to Day 9 (Part A: treatment period 2) and at follow-up 4-14 days after discharge.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics of AZD1386 in plasma</measure>
    <time_frame>Assessments performed at frequent timepoints (predose then ranging from 15 minutes to every 12 hours) on Days -1 to Day 3 (Part A: treatment period 1 and Part B) or Day-1 to Day 9 (Part A: treatment period 2).</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for AZD1386</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo for Naproxen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1386</intervention_name>
    <description>Single ascending and multiple (twice daily) oral doses, capsule</description>
    <arm_group_label>Part A: A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for AZD1386</intervention_name>
    <description>Single ascending and multiple (twice daily) oral doses, capsule</description>
    <arm_group_label>Part A: B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Tablet, single oral dose, 500mg</description>
    <arm_group_label>Part B: A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Naproxen</intervention_name>
    <description>Tablet, single oral dose</description>
    <arm_group_label>Part B: B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed, written and dated informed consent prior to any study specific
             procedures

          -  Healthy male and female (of non childbearing potential)

          -  Body Mass Index (BMI) of ≥19 to ≤28 kg/m2 and a weight of ≥50 to ≤100 kg

        Exclusion Criteria:

          -  History or presence of any clinically significant disease or disorder in the opinion
             of the investigator.

          -  Any clinically relevant abnormal findings in physical examination, clinical chemistry,
             haematology, urinalysis, vital signs or ECG at baseline in the opinion of the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Leff</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Pharmaceuticals, Wilmington, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Tania Hugo</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit, London UK.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Healthy</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

